Skip to content
Rapid VentRapid Vent Calculator

Rocuronium vs succinylcholine for adult RSI: compare doses, onset, and the evidence

Published 

Rocuronium vs succinylcholine for RSI comes down to duration and safety limits more than speed. By their FDA labels, succinylcholine’s block develops in about 1 minute and recovers within minutes, while rocuronium at its higher labeled RSI dose reaches peak block in about 1 minute and lasts about 67 minutes. The faster-clearing drug still carries a label warning list, including hyperkalemia risk after the acute phase of major burns or multiple trauma, that the longer-acting one doesn’t share. SCCM’s 2023 guideline suggests either one when succinylcholine is not contraindicated. Adult patients only; the protocol decides. Rapid Vent Calculator’s hub puts RSI medications with both paralytics side by side in one table.

Rocuronium vs succinylcholine: what the labels and sources state
ComparedSuccinylcholineRocuronium
ClassDepolarizing neuromuscular blocking agent (FDA label)Non-depolarizing neuromuscular blocking agent (FDA label)
Label intubating doseAverage 0.6 mg/kg; adult range 0.3 to 1.1 mg/kg (FDA label)Rapid sequence intubation 0.6 to 1.2 mg/kg in “appropriately premedicated and adequately anesthetized patients” (FDA label)
Other published figures1.5 mg/kg (StatPearls NBK459276); 1 to 1.5 mg/kg as a study’s own definition of appropriate ED dosing (Bhat 2016); 1 mg/kg as the trial “gold standard” (Putzu 2020)1 mg/kg (StatPearls NBK459276)
Onset (label)Block develops in about 1 minuteTime to maximum block 1.8 min at 0.6 mg/kg; 1.0 min at the higher RSI dose
Duration (label)Maximum block may persist about 2 minutes, then recovery within 4 to 6 minutesClinical duration 31 min at 0.6 mg/kg; 67 min at 1.2 mg/kg
Label contraindicationsSkeletal muscle myopathies; known hypersensitivity; after the acute phase of major burns, multiple trauma, extensive denervation, or upper motor neuron injury; known or suspected genetic susceptibility to malignant hyperthermiaKnown hypersensitivity to rocuronium bromide or other neuromuscular blocking agents
ReversalNo reversal agent named for the routine block in the labelSugammadex is labeled for reversal of rocuronium- or vecuronium-induced block in patients undergoing surgery (BRIDION label)
Weight in obesityActual body weight (Erstad and Barletta 2021; Lemmens and Brodsky 2006)Split: the label bases its initial dose on actual weight (FDA label); a 2021 review suggests ideal or adjusted weight for the class (Erstad and Barletta 2021)

Figures are what each source reports, not a dosing instruction. The label figures come from anesthesia settings. The crew’s protocol sets the paralytic and the dose.

Rocuronium vs succinylcholine doses: where 1 mg/kg and 1.5 mg/kg come from

Rapid Vent Calculator multiplies rocuronium at 1 mg/kg and succinylcholine at 1.5 mg/kg by the entered actual weight: the first sits inside its label’s RSI range, the second above its label’s adult range. That’s the app’s medications card, not a citation.

StatPearls gives 1 mg/kg for rocuronium, inside the label’s RSI range. rocuronium RSI dose studies above 1.2 mg/kg go deeper on that dose.

The trials below used their own doses: Cochrane’s floor was rocuronium 0.6 mg/kg and succinylcholine 1 mg/kg; CURASMUR used a higher rocuronium dose still.

Sources agree on actual weight for succinylcholine and split for rocuronium in obesity. actual vs ideal body weight for both paralytics lays out that split.

Sources differ, and the protocol sets it. The FDA label gives an average dose of 0.6 mg/kg, with an adult range of 0.3 to 1.1 mg/kg, noting that “the optimum intravenous dose… will vary among patients.” StatPearls prints 1.5 mg/kg for intubation. Bhat and colleagues (2016), in a single-ED chart review, defined appropriate ED dosing as 1 to 1.5 mg/kg of total body weight. Putzu and colleagues (2020), in a meta-analysis of six randomized trials in 864 surgical adults aged 18 to 65 (obese patients excluded), call 1 mg/kg the gold-standard regimen and found doses at or below 0.5 mg/kg less likely to give excellent conditions. The calculator’s figure sits above the labeled range.

Compare onset and duration: succinylcholine vs rocuronium

Rocuronium lasts far longer. At the label’s own doses, succinylcholine’s block develops in about 1 minute, maximum block may persist about 2 minutes, and recovery follows within 4 to 6 minutes. Rocuronium’s clinical duration runs 31 minutes at 0.6 mg/kg and 67 minutes at 1.2 mg/kg, with peak block reached in about 1.8 minutes and 1.0 minute at those doses. Onset at its larger dose approaches succinylcholine’s; duration does not.

The field datum is an EMS registry of Seattle-area adults not in cardiac arrest: median time from paralytic to first laryngoscopy attempt was 57 seconds for succinylcholine and 83 seconds for rocuronium, a measure of time to first attempt, not onset (Ramsey 2024). First-attempt success, 84% versus 83%, was similar.

What is the difference between rocuronium and suxamethonium?

Succinylcholine, called suxamethonium in many countries outside the US, is a depolarizing paralytic. Rocuronium is non-depolarizing. By their labels, the first combines with the motor end plate’s cholinergic receptors to produce depolarization, which may appear as fasciculations; the second competitively blocks acetylcholine receptors at the same site.

Succinylcholine vs rocuronium: block onset and duration on the FDA labelsA horizontal timeline from 0 to 90 minutes, ticks every 15 minutes. A light band from 0 to 10 minutes marks induction agents by label: etomidate 3 to 5 minutes, ketamine 5 to 10 minutes. Succinylcholine (label, doses of 0.3 to 1.1 mg/kg): a short bar with three phases drawn in sequence, block in about 1 minute, maximum block that may persist about 2 minutes, then recovery within 4 to 6 minutes; the label gives no summed total. Rocuronium 0.6 mg/kg (label, adults 18 to 64): peak block marker at 1.8 minutes, median clinical duration 31 minutes with a range whisker from 15 to 85 minutes. Rocuronium’s higher labeled RSI dose, 1.2 mg/kg (label, adults 18 to 64): peak block marker at 1.0 minute, median clinical duration 67 minutes with a range whisker from 38 minutes, clipped at the 90-minute axis edge with the text “to 160” marking that the reported range continues to 160 minutes. No drug is highlighted as preferred.Induction agents by label: etomidate 3-5 min, ketamine 5-10 min0153045607590 minSuccinylcholine 0.3-1.1 mg/kg: block ~1 min, max block ~2 min, recovery within 4-6 minRocuronium 0.6 mg/kg: peak 1.8 min, median 31 min (15 to 85)to 160Rocuronium 1.2 mg/kg: peak 1.0 min, median 67 min (38 to 160)
Label figures from anesthesia settings (FDA succinylcholine and rocuronium labels; induction-agent durations from their FDA labels). Emergency conditions may differ. None of this is a dosing instruction or a recommendation of either drug.

When should succinylcholine be avoided?

The succinylcholine label lists four contraindications; the rocuronium label just one, quoted here as label text, not instructions.

Succinylcholine is contraindicated “in patients with skeletal muscle myopathies,” “in patients with known hypersensitivity to succinylcholine,” “after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest,” and “in patients with known or suspected genetic susceptibility to malignant hyperthermia.” Its warnings add that it “may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia,” that malignant hyperthermia “may occur, especially in individuals with known or suspected susceptibility,” and that bradycardia’s incidence “is higher following a second dose.”

Rocuronium’s label states it “is contraindicated in patients known to have hypersensitivity… to rocuronium bromide or other neuromuscular blocking agents.”

Simmer and colleagues (2026), in a retrospective study of 434 ED adults with an initial potassium above 5.5 mmol/L, found no significant difference in 24-hour mortality between rocuronium (10.0%) and succinylcholine (10.5%), writing that the finding “questions the presumed clinical importance of potassium levels in paralytic selection for RSI.” That population is pre-existing hyperkalemia, different from the label’s post-injury contraindication; the finding sits beside the label, not over it.

The clinician and the protocol decide which applies.

Compare the evidence: rocuronium versus succinylcholine in trials and registries

It depends on the outcome and the setting. A Cochrane review found succinylcholine gave excellent intubating conditions more often. A prehospital trial could not show rocuronium was non-inferior on first-attempt success. ED and EMS registries found similar first-pass success between them.

  • Cochrane (Tran 2015): 50 trials, 4,151 participants, in any age group or clinical setting (five pediatric trials among them, 536 participants), mostly elective or non-emergent. Excellent conditions RR 0.86 (0.81 to 0.92); no statistical difference against rocuronium 1.2 mg/kg (3 trials, 86 participants). The authors concluded succinylcholine was “clinically superior as it has a shorter duration of action.”
  • CURASMUR (Guihard 2019, JAMA): 1,248 adults, 17 French physician-staffed out-of-hospital emergency units. Rocuronium 1.2 mg/kg versus succinylcholine 1 mg/kg. First-attempt success 74.6% versus 79.4%; rocuronium “failed to demonstrate noninferiority.”
  • NEAR registry (2018, Ann Emerg Med): 22 EDs, patients older than 14. First-pass success 87.0% versus 87.5%, succinylcholine first (adjusted OR 0.9, 0.6 to 1.3); adverse events 14.7% versus 14.8%.
  • O’Connell 2026 (West J Emerg Med): a retrospective TriNetX database study of propensity-matched adults given etomidate (26,884). 60-day mortality 30.1% versus 33.4% (RR 0.901) and myocardial infarction 10.5% versus 11.9%, both lower with succinylcholine; the authors note the design cannot establish causation and unmeasured conditions could confound it.
  • SCCM 2023 and Engstrom 2023: SCCM’s guideline “suggests administering either rocuronium or succinylcholine for RSI when there are no known contraindications to succinylcholine” (conditional, low quality). Engstrom’s review found “minimal differences between succinylcholine and high dose rocuronium in first-pass success rates.”

When to use sux vs roc: what the guideline describes

The sources differ on whether one paralytic is the default choice. SCCM’s 2023 guideline suggests either (a conditional recommendation on low-quality evidence). The Cochrane review’s authors concluded in 2015 that succinylcholine “should still be used as a first-line muscle relaxant” and that rocuronium, if used, “should only be used as a second-line treatment because the length of paralysis will be significantly prolonged.” Each is that source’s own conclusion, not a site recommendation.

The label warnings above are where the sources point away from succinylcholine; its shorter block is what the Cochrane authors weighed in its favor. Which paralytic a crew carries and pushes is set by the agency’s formulary, protocol, and medical direction before it is ever a preference.

After the push: reversal and the sedation gap

Rocuronium’s block far outlasts both induction agents in the figure above. Two ED studies disagree on whether that delays sedation. Carlson and colleagues (2023), in a multicenter retrospective study of 200 ED adults, found no difference in median time to analgesia or sedation (10 minutes with succinylcholine versus 8.5 with rocuronium). Hwang and colleagues (2025), in a retrospective study of 2,059 ED adults across three EDs induced with etomidate, found a longer median time to sedation with rocuronium (12 versus 10 minutes) and lower rates of sedation (adjusted hazard ratio 0.75) and analgesia (0.73), concluding that patients given rocuronium “are at increased risk of being awake during paralysis.” ED-AWARENESS found exposure to it associated with awareness with paralysis in ventilated ED adults. Neither study is ranked over the other here.

Sugammadex for rocuronium, and what the succinylcholine label says

Rocuronium has a labeled agent for its block, sugammadex. A routine succinylcholine block wears off on its own; the label names nothing for it outside Phase II. BRIDION’s indication reads “reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide” in patients undergoing surgery, and its warnings exclude “nonsteroidal neuromuscular blocking agents such as succinylcholine.” No BRIDION dose prints here, and whether it’s carried is a formulary matter.

Verify both paralytic doses against the patient

Rapid Vent Calculator’s medications card lists both drugs under “NEUROMUSCULAR BLOCKERS,” each with its scalar and a whole-milligram result from the entered actual weight. It does not choose between them, screen for contraindications, know the potassium, or know about a burn, a myopathy, or a malignant hyperthermia history. The arithmetic is identical whichever drug the protocol calls for; everything that separates the two drugs above is something only the crew can see.

After the paralytic: sedation scoring and the first vent settings

The rocuronium label states it “has no known effect on consciousness, pain threshold, or cerebration,” requiring “adequate anesthesia or sedation.” Succinylcholine’s label agrees: “no effect on consciousness, pain threshold or cerebration.”

Sedation after either paralytic is scored on a scale (NASEMSO v3.0). A paralyzed patient can’t be scored until the block wears off; the scale’s own validation excluded patients under neuromuscular blockade. the RASS scale once the paralytic wears off covers the scale itself.

From there, tidal volume switches to ideal body weight, not the actual weight either dose used. the first ventilator settings after either paralytic picks up from there, and post-intubation vent checks on a paralyzed patient carries it further. Drug order is its own question: the induction agent vs paralytic sequence covers it.

Sources

  1. US Food and Drug Administration. Succinylcholine chloride injection prescribing information (Camber Pharmaceuticals / Aspiro Pharma). DailyMed; revised November 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3deac02b-392c-4ee4-9abf-7fe5b8975147
  2. US Food and Drug Administration. Rocuronium bromide injection prescribing information (Hospira). DailyMed; revised June 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309aeb1b-8022-4df7-8194-ae6529e3395c
  3. US Food and Drug Administration. BRIDION (sugammadex) injection prescribing information (Merck Sharp & Dohme). DailyMed; revised March 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5171d883-fe8f-482c-97ab-40b00975b64a
  4. Tran DTT, Newton EK, Mount VAH, Lee JS, Wells GA, Perry JJ. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database of Systematic Reviews. 2015;(10):CD002788. https://pmc.ncbi.nlm.nih.gov/articles/PMC7104695/
  5. Guihard B, Chollet-Xémard C, Lakhnati P, et al. Effect of rocuronium vs succinylcholine on endotracheal intubation success rate among patients undergoing out-of-hospital rapid sequence intubation: a randomized clinical trial. JAMA. 2019;322(23):2303-2312. https://pmc.ncbi.nlm.nih.gov/articles/PMC6990819/
  6. Acquisto NM, Mosier JM, Bittner EA, et al. Society of Critical Care Medicine clinical practice guidelines for rapid sequence intubation in the critically ill adult patient. Critical Care Medicine. 2023;51(10):1411-1430. https://pubmed.ncbi.nlm.nih.gov/37707379/
  7. April MD, Arana A, Pallin DJ, et al. Emergency department intubation success with succinylcholine versus rocuronium: a National Emergency Airway Registry study. Annals of Emergency Medicine. 2018;72(6):645-653. https://pubmed.ncbi.nlm.nih.gov/29747958/
  8. Hendrix JM, Regunath H. Intubation Endotracheal Tube Medications. In: StatPearls. StatPearls Publishing; updated January 19, 2025. NCBI Bookshelf NBK459276. https://www.ncbi.nlm.nih.gov/books/NBK459276/
  9. Putzu A, Tramèr MR, Giffa M, Czarnetzki C. The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials. BMC Anesthesiology. 2020;20:54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7053066/
  10. Bhat R, Mazer-Amirshahi M, Sun C, et al. Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED. American Journal of Emergency Medicine. 2016;34(12):2423-2425. https://pubmed.ncbi.nlm.nih.gov/27727068/
  11. Ramsey JT, Pache KM, Sayre MR, Maynard C, Johnson NJ, Counts CR. Comparison of intubating conditions with succinylcholine versus rocuronium in the prehospital setting. Prehospital Emergency Care. 2024;28(4):537-544. https://pubmed.ncbi.nlm.nih.gov/38019685/
  12. O’Connell DH, Yeager J, Abrams RA, et al. Outcomes of succinylcholine and rocuronium for rapid sequence intubation in the emergency department. Western Journal of Emergency Medicine. 2026;27(3):766-774. https://pmc.ncbi.nlm.nih.gov/articles/PMC13246191/
  13. Simmer PE, Perza M, Cho YD, Boustila E, Stowens JC. Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: retrospective study of clinical outcomes. American Journal of Emergency Medicine. 2026;100:154-164. https://pubmed.ncbi.nlm.nih.gov/41380422/
  14. Carlson RT, Shah S, Wells E, Fertel BS, Campbell MJ. Post-intubation analgesia and sedation following succinylcholine vs. rocuronium in the emergency department. American Journal of Emergency Medicine. 2023;71:99-103. https://pubmed.ncbi.nlm.nih.gov/37356339/
  15. Hwang C, Michaels B, Park K, Dang A, Vo C, Lee S, Coralic Z. Impact of paralytic choice on postintubation sedation and analgesia in the emergency department. American Journal of Health-System Pharmacy. 2025;82(Supplement_3):S2929-S2936. https://pubmed.ncbi.nlm.nih.gov/40037283/
  16. Pappal RD, Roberts BW, Mohr NM, et al. The ED-AWARENESS study: a prospective, observational cohort study of awareness with paralysis in mechanically ventilated patients admitted from the emergency department. Annals of Emergency Medicine. 2021;77(5):532-544. https://pmc.ncbi.nlm.nih.gov/articles/PMC8166299/
  17. Engstrom K, Brown CS, Mattson AE, Lyons N, Rech MA. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. American Journal of Emergency Medicine. 2023;70:19-29. https://pubmed.ncbi.nlm.nih.gov/37196592/
  18. Erstad BL, Barletta JF. Dosing of neuromuscular blocking agents in patients with obesity: a narrative review. Anaesthesia and Intensive Care. 2021;49(2):98-104. https://pubmed.ncbi.nlm.nih.gov/33906465/
  19. Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesthesia and Analgesia. 2006;102(2):438-442. https://pubmed.ncbi.nlm.nih.gov/16428539/
  20. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. American Journal of Respiratory and Critical Care Medicine. 2002;166(10):1338-1344. https://pubmed.ncbi.nlm.nih.gov/12421743/
  21. NASEMSO Medical Directors Council. National Model EMS Clinical Guidelines, Version 3.0. National Association of State EMS Officials; March 2022.
  22. Kuhl EA, Perera TB. Prehospital Mechanical Ventilation. In: StatPearls. StatPearls Publishing; updated March 8, 2024. NCBI Bookshelf NBK537072. https://www.ncbi.nlm.nih.gov/books/NBK537072/
  23. US Food and Drug Administration. Ketamine Hydrochloride Injection, USP (CIII) prescribing information (Civica, Inc.). DailyMed; revised June 2026.
  24. US Food and Drug Administration. AMIDATE (etomidate) injection prescribing information (Hospira, Inc.). DailyMed; revised April 2022.